KR101075324B1 - 항염증 활성을 가지는 특이적 글루코코르티코스테로이드화합물 - Google Patents
항염증 활성을 가지는 특이적 글루코코르티코스테로이드화합물 Download PDFInfo
- Publication number
- KR101075324B1 KR101075324B1 KR1020067000738A KR20067000738A KR101075324B1 KR 101075324 B1 KR101075324 B1 KR 101075324B1 KR 1020067000738 A KR1020067000738 A KR 1020067000738A KR 20067000738 A KR20067000738 A KR 20067000738A KR 101075324 B1 KR101075324 B1 KR 101075324B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- oxo
- hydroxy
- oxy
- diene
- Prior art date
Links
- 0 CCC(C(C)C1)C(CCC(CC=C2)=CC2=O)C(C[C@@](C)[C@@]2(C(*)S)O)C12[Cn] Chemical compound CCC(C(C)C1)C(CCC(CC=C2)=CC2=O)C(C[C@@](C)[C@@]2(C(*)S)O)C12[Cn] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
Abstract
Description
Claims (34)
- 하기 화학식(I)의 화합물 또는 이의 생리학적으로 허용되는 염 또는 용매화물:상기 식에서,X는 O 또는 S를 나타내고;R1은 C1-6 알킬, C3-8 시클로알킬, C3-8 시클로알킬메틸 또는 C3-8 시클로알케닐 (이들 중 임의의 것은 하나 이상의 메틸기 또는 할로겐 원자로 치환되거나 비치환될 수 있음)을 나타내거나, R1은 아릴, 치환된 아릴, 헤테로아릴 또는 치환된 헤테로아릴을 나타내고;R2는 수소, α 또는 β 배열일 수 있는 메틸, 또는 메틸렌을 나타내고;R3 및 R4는 동일하거나 상이하며, 각각 독립적으로 수소, 할로겐 또는 메틸기를 나타내고;
- 제 1 항에 있어서, X는 O를 나타냄을 특징으로 하는 화합물.
- 제 1 항에 있어서, R1이 하나 이상의 메틸 또는 염소기에 의해 치환되거나 비치환된 C3-6 시클로알킬기를 나타냄을 특징으로 하는 화합물.
- 제 1 항에 있어서, R1이 2,2,3,3-테트라메틸시클로프로필을 나타냄을 특징으로 하는 화합물.
- 제 1 항에 있어서, R2가 α-배열의 메틸을 나타냄을 특징으로 하는 화합물.
- 제 1 항에 있어서, R3 및 R4 둘 모두가 플루오르임을 특징으로 하는 화합물.
- 제 1 항에 있어서,6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;17α-(4-[(디에틸아미노)설포닐]벤조일)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;17α-(5-클로로-4-메톡시-티오펜-3-카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;17α-(시클로헥실카르보닐)옥시-6α,9α-디플루오로-1lβ-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-17α-(2,6-디플루오로벤조일)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-17α-(4-메톡시벤조일)옥시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;17α-(4-시아노벤조일)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;17α-(시클로펜틸메틸카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-17α-(3,3-디메틸부타노일)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-17α-(2-이소프로필-1,3-티아졸-4-카르보닐)옥시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(퀴놀린-2-카르보닐)옥시-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(5-트리플루오로메틸-푸란-2-카르보닐)옥시-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-16α-메틸-17α-(5-메틸설포닐-티오펜-2-카르보닐)옥시-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-16α-메틸-17α-(5-메틸티오-티오펜-2-카르보닐)옥시-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-17α-(5-에틸-이속사졸-3-카르보닐)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;9α-플루오로-11β-하이드록시-16β-메틸-3-옥소-17α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-4-엔-17β-카르복실산 시아노메틸 에스테르;17α-(5-클로로-4-메톡시-티오펜-3-카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;17α-(2,2-디클로로-3,3-디메틸시클로프로필카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;17α-(2,2-디클로로-3,3-디메틸시클로프로필카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;17α-(시클로헥실카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-16α-메틸-17α-(5-메틸설포닐-티오펜-2-카르보닐)옥시-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(5-트리플루오로메틸-푸란-2-카르보닐)옥시-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르; 또는6α,9α-디플루오로-17α-(3-(디플루오로메틸티오)벤조일)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르인임을 특징으로 하는 화합물.
- 제 8 항에 있어서,6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;9α-플루오로-11β-하이드록시-16β-메틸-3-옥소-17α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;17α-(시클로헥실카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;17α-(시클로펜틸메틸카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-17α-(3,3-디메틸부타노일)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-17α-(3-(디플루오로메틸티오)벤조일)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;17α-(시클로헥실카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;6α,9α-디플루오로-17α-(5-에틸-이속사졸-3-카르보닐)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-16α-메틸-17α-(5-메틸티오-티오펜-2-카르보닐)옥시-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-17α-(2-이소프로필-1,3-티아졸-4-카르보닐)옥시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;17α-(2,2-디클로로-3,3-디메틸시클로프로필카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르; 또는17α-(2,2-디클로로-3,3-디메틸시클로프로필카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르임을 특징으로 하는 화합물.
- 제 9 항에 있어서,17α-(2,2-디클로로-3,3-디메틸시클로프로필카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르; 또는6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르임을 특징으로 하는 화합물.
- 삭제
- 삭제
- 염증 질환, 알레르기 질환, 또는 염증 질환 및 알레르기 질환 둘 모두를 가진 환자의 치료에서의 사용을 위한, 제 1 항에 따른 화학식(I)의 화합물 또는 이의 생리학적으로 허용되는 염 또는 용매화물.
- 제 13 항에 있어서, 상기 염증 질환, 알레르기 질환, 또는 염증 질환 및 알레르기 질환 둘 모두가 습진, 건선, 알레르기성 피부염, 신경성 피부염, 소양증, 과민반응, 천식, 비염, 비 폴립(nasal polyps), 만성 폐쇄성 폐 질환, 간질성 폐질환, 섬유증, 궤양성 대장염, 크론병, 류머티즘성 관절염 및 결막염으로부터 선택되는 것을 특징으로 하는, 환자의 치료에 사용하기 위한 화학식(I)의 화합물 또는 이의 생리학적으로 허용되는 염 또는 용매화물.
- 제 14항에 있어서, 상기 염증 질환, 알레르기 질환, 또는 염증 질환 및 알레르기 질환 둘 모두가 알레르기성 피부염임을 특징으로 하는, 환자의 치료에 사용하기 위한 화학식(I)의 화합물 또는 이의 생리학적으로 허용되는 염 또는 용매화물.
- 제 14항에 있어서, 상기 염증 질환, 알레르기 질환, 또는 염증 질환 및 알레르기 질환 둘 모두가 천식임을 특징으로 하는, 환자의 치료에 사용하기 위한 화학식(I)의 화합물 또는 이의 생리학적으로 허용되는 염 또는 용매화물.
- 제 14항에 있어서, 상기 염증 질환, 알레르기 질환, 또는 염증 질환 및 알레르기 질환 둘 모두가 비염임을 특징으로 하는, 환자의 치료에 사용하기 위한 화학식(I)의 화합물 또는 이의 생리학적으로 허용되는 염 또는 용매화물.
- 제 14항에 있어서, 상기 염증 질환, 알레르기 질환, 또는 염증 질환 및 알레르기 질환 둘 모두가 비 폴립임을 특징으로 하는, 환자의 치료에 사용하기 위한 화학식(I)의 화합물 또는 이의 생리학적으로 허용되는 염 또는 용매화물.
- 제 14항에 있어서, 상기 염증 질환, 알레르기 질환, 또는 염증 질환 및 알레르기 질환 둘 모두가 결막염임을 특징으로 하는, 환자의 치료에 사용하기 위한 화학식(I)의 화합물 또는 이의 생리학적으로 허용되는 염 또는 용매화물.
- 삭제
- 제 1 항에 따른 화학식(I)의 화합물 또는 이의 생리학적으로 허용되는 염 또는 용매화물을 하나 이상의 생리학적으로 허용되는 희석제 또는 담체와 혼합하여 포함하는, 염증 질환, 알레르기 질환, 또는 염증 질환 및 알레르기 질환 둘 모두의 치료를 위한 약제 조성물.
- 제 21 항에 있어서, 상기 화학식(I)의 화합물 또는 이의 생리학적으로 허용되는 염 또는 용매화물이 경구, 협측, 설하, 비경구, 국부 또는 직장 투여용으로 제형화됨을 특징으로 하는 약제 조성물.
- 제 22 항에 있어서, 상기 화학식(I)의 화합물 또는 이의 생리학적으로 허용되는 염 또는 용매화물이 국부 투여용으로 제형화되고, 연고, 로션, 크림, 겔, 포움(foam), 경피성 패치에 의한 전달용 제제, 분말, 스프레이, 에어로졸, 흡입기 또는 취입기 또는 점적약에 사용하기 위한 캡슐 또는 카트리지, 분무를 위한 용액/현탁액, 좌제, 페서리, 정체 관장약, 씹을 수 있는 정제, 빨아 먹을 수 있는 정제, 펠릿, 리포솜 제제 또는 미소캡슐화 제제로 구성된 군으로부터 선택됨을 특징으로 하는, 약제 조성물.
- 제 1 항에 따른 화학식(I)의 화합물 또는 이의 생리학적으로 허용되는 염 또는 용매화물, 및 추진제로서 플루오로탄소 또는 수소-함유 클로로플루오로 탄소와, 임의로 계면활성제, 공용매 또는 계면활성제 및 공용매 둘 모두와 조합하여 포함하는, 염증 질환, 알레르기 질환, 또는 염증 질환 및 알레르기 질환 둘 모두의 치료를 위한 약학적 에어로졸 제형.
- 제 24 항에 있어서, 상기 추진제가 1,1,1,2-테트라플루오로에탄, 1,1,1,2,3,3,3-헵타플루오로-n-프로판 또는 이들의 혼합물로부터 선택됨을 특징으로 하는 약학적 에어로졸 제형.
- 약학적으로 허용되는 희석제 또는 담체와 함께 하나 이상의 다른 치료적 활성제와 조합된 제 1 항에 따른 화학식(I)의 화합물 또는 이의 생리적으로 허용되는 염 또는 용매화물을 포함하는, 염증 질환, 알레르기 질환, 또는 염증 질환 및 알레르기 질환 둘 모두의 치료를 위한 약학적 제형.
- 제 26 항에 있어서, 상기 또 다른 치료용 활성제가 β2-아드레날린수용제 효능제임을 특징으로 하는 약학적 제형.
- 제 26 항에 있어서, 상기 다른 치료적 활성제가 PDE4 억제제임을 특징으로 하는 약학적 제형.
- 제 26 항에 있어서, 상기 다른 치료적 활성제가 항콜린제임을 특징으로 하는 약학적 제형.
- 제 26 항에 있어서, 상기 다른 치료적 활성제가 항히스타민제임을 특징으로 하는 약학적 제형.
- 17α-(4-[(디에틸아미노)설포닐]벤조일)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산;6α,9α-디플루오로-17α-(2,6-디플루오로벤조일)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;6α,9α-디플루오로-11β-하이드록시-17α-(4-메톡시벤조일)옥시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;17α-(4-시아노벤조일)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;6α,9α-디플루오로-17α-(3,3-디메틸부타노일)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;6α,9α-디플루오로-11β-하이드록시-17α-(2-이소프로필-1,3-티아졸-4-카르보닐)옥시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(퀴놀린-2-카르보닐)옥시-안드로스타-1,4-디엔-17β-카르복실산;6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(5-트리플루오로메틸-푸란-2-카르보닐)옥시-안드로스타-1,4-디엔-17β-카르복실산;6α,9α-디플루오로-11β-하이드록시-16α-메틸-17α-(5-메틸설포닐-티오펜-2-카르보닐)옥시-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;6α,9α-디플루오로-11β-하이드록시-16α-메틸-17α-(5-메틸티오-티오펜-2-카르보닐)옥시-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;6α,9α-디플루오로-17α-(5-에틸-이속사졸-3-카르보닐)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;17α-(5-클로로-4-메톡시-티오펜-3-카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;17α-(2,2-디클로로-3,3-디메틸시클로프로필카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;17α-(2,2-디클로로-3,3-디메틸시클로프로필카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산;6α,9α-디플루오로-11β-하이드록시-16α-메틸-17α-(5-메틸설포닐-티오펜-2-카르보닐)옥시-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산;6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(5-트리플루오로메틸-푸란-2-카르보닐)옥시-안드로스타-1,4-디엔-17β-카르보티오산, 또는6α,9α-디플루오로-17α-(3-(디플루오로메틸티오)벤조일)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산임을 특징으로 하는 화합물.
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0316290.6A GB0316290D0 (en) | 2003-07-11 | 2003-07-11 | Novel compounds |
GB0316290.6 | 2003-07-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060052807A KR20060052807A (ko) | 2006-05-19 |
KR101075324B1 true KR101075324B1 (ko) | 2011-10-19 |
Family
ID=27742019
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067000690A KR101029207B1 (ko) | 2003-07-11 | 2004-07-09 | 소염 활성을 지니는 특정 글루코코르티코스테로이드 화합물 |
KR1020067000738A KR101075324B1 (ko) | 2003-07-11 | 2004-07-09 | 항염증 활성을 가지는 특이적 글루코코르티코스테로이드화합물 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067000690A KR101029207B1 (ko) | 2003-07-11 | 2004-07-09 | 소염 활성을 지니는 특정 글루코코르티코스테로이드 화합물 |
Country Status (31)
Country | Link |
---|---|
US (6) | US7291609B2 (ko) |
EP (3) | EP1644397B1 (ko) |
JP (3) | JP4709751B2 (ko) |
KR (2) | KR101029207B1 (ko) |
CN (3) | CN102372756A (ko) |
AR (2) | AR045900A1 (ko) |
AT (1) | ATE467638T1 (ko) |
AU (2) | AU2004255854B2 (ko) |
BR (2) | BRPI0412526A (ko) |
CA (2) | CA2531911C (ko) |
CY (2) | CY1110149T1 (ko) |
DE (1) | DE602004027137D1 (ko) |
DK (2) | DK1644398T3 (ko) |
ES (3) | ES2343685T3 (ko) |
GB (1) | GB0316290D0 (ko) |
HK (2) | HK1089185A1 (ko) |
HR (2) | HRP20100359T1 (ko) |
IL (3) | IL172776A (ko) |
IS (3) | IS2909B (ko) |
MA (2) | MA27897A1 (ko) |
MX (2) | MXPA06000442A (ko) |
MY (2) | MY140987A (ko) |
NO (2) | NO333263B1 (ko) |
NZ (2) | NZ544577A (ko) |
PL (2) | PL1644397T3 (ko) |
PT (2) | PT1644398E (ko) |
RU (3) | RU2359973C2 (ko) |
SI (2) | SI1644397T1 (ko) |
TW (2) | TWI367888B (ko) |
WO (2) | WO2005005452A1 (ko) |
ZA (2) | ZA200600223B (ko) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0125259D0 (en) * | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
DE102004025985A1 (de) * | 2004-05-21 | 2005-12-15 | Schering Ag | Estriol- und Estetrol-Prodrugs |
DE102004025966A1 (de) * | 2004-05-21 | 2005-12-15 | Schering Ag | Estradiol-Prodrugs |
JP5281291B2 (ja) * | 2005-01-10 | 2013-09-04 | グラクソ グループ リミテッド | 新規化合物 |
US20090124588A1 (en) * | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
US20090298802A1 (en) * | 2005-03-30 | 2009-12-03 | Sequeira Joel A | Pharmaceutical Compositions |
CA2615173C (en) | 2005-07-14 | 2012-01-03 | Lipothera, Inc. | Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
TW200811111A (en) | 2006-04-20 | 2008-03-01 | Glaxo Group Ltd | Novel compounds |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
PL2077830T3 (pl) * | 2006-10-17 | 2013-04-30 | Lithera Inc | Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej |
PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
EA019819B1 (ru) | 2008-05-23 | 2014-06-30 | ПАНМИРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Кристаллическая полиморфная форма с ингибитора белка, активирующего 5-липоксигеназу, фармацевтическая композиция на ее основе и применение в лечении |
WO2009147187A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
US20100160351A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
EP2406249A1 (en) | 2009-03-10 | 2012-01-18 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
US20120058984A1 (en) | 2009-03-17 | 2012-03-08 | Catherine Mary Alder | Pyrimidine derivatives used as itk inhibitors |
US20120035247A1 (en) | 2009-03-19 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
EP2408915A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
MX2011009724A (es) | 2009-03-19 | 2011-10-14 | Merck Sharp & Dohme | Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen del factor de transcripcion basico de cierre de leucina 1 de homologia de btb y cnc 1, usando el listado de secuencias de acido nucleico corto de interferencia. |
WO2010107952A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120022142A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20120022143A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA) |
AU2010229847A1 (en) | 2009-03-27 | 2011-10-13 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of the intercellular adhesion molecule 1 (ICAM-1)gene expression using short interfering nucleic acid (siNA) |
JP2012521762A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた神経成長因子β鎖(NGFβ)遺伝子発現のRNA干渉媒介性阻害 |
US20120010272A1 (en) | 2009-03-27 | 2012-01-12 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
WO2010122089A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | N-pyrazolyl carboxamides as crac channel inhibitors |
WO2010122088A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
DK2899191T3 (da) | 2009-04-30 | 2017-11-13 | Glaxo Group Ltd | Oxazol-substituerede indazoler som pi3-kinaseinhibitorer |
US9132084B2 (en) * | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
WO2010136940A1 (en) * | 2009-05-29 | 2010-12-02 | Pfizer Limited | Novel glucocorticoid receptor agonists |
WO2011032175A1 (en) | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
EP2507231A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
US20120238559A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Novel compounds |
WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
AU2011205646B2 (en) * | 2010-01-15 | 2014-10-02 | Neothetics, Inc. | Lyophilized cake formulations |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
ES2602972T3 (es) | 2010-09-08 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe |
SI2614058T1 (sl) | 2010-09-08 | 2015-10-30 | Glaxosmithkline Intellectual Property Development Limited | Polimorfi in soli N-(5-(4-(5-(((2R,6S)-2,6-dimetil-4-morfolinil)metil)-1,3-oksazol-2-il)- 1H-indazol-6-il)-2-(metiloksi)-3-piridinil)metansulfonamida |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
US9156791B2 (en) | 2010-10-21 | 2015-10-13 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
US9597531B2 (en) | 2010-11-24 | 2017-03-21 | Neothetics, Inc. | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
EP2678338B1 (en) | 2011-02-25 | 2015-09-09 | Novartis AG | Pyrazolo[1,5-a]pyridines as trk inhibitors |
US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
WO2014198909A1 (en) | 2013-06-14 | 2014-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Rac1 inhibitors for inducing bronchodilation |
CA2923995A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
US20160263109A1 (en) | 2013-10-17 | 2016-09-15 | Glaxosmithkline Intellectual Property Development Limited | P13k inhibitor for treatment of respiratory disease |
SG11201609276RA (en) | 2014-05-12 | 2016-12-29 | Glaxosmithkline Ip No 2 Ltd | Pharmaceutical compositions comprising danirixin for treating infectious diseases |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US20190161480A1 (en) | 2016-08-08 | 2019-05-30 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US11759472B2 (en) | 2017-11-21 | 2023-09-19 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
JP7440419B2 (ja) * | 2017-11-21 | 2024-02-28 | アクセロビジョン インコーポレイテッド | 眼周囲分泌腺におけるまたは眼表面での異常な炎症を処置するための組成物および使用方法 |
JP2023519585A (ja) | 2020-03-26 | 2023-05-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | ウイルス感染を予防または治療するカテプシン阻害剤 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3856828A (en) | 1972-07-19 | 1974-12-24 | Glaxo Lab Ltd | Anti-inflammatory steroids of the androstane series having a halo-substituted c{11 {14 c{11 {11 alkoxy carbonyl group at the 17{62 {0 position |
GB1514476A (en) | 1974-08-30 | 1978-06-14 | Glaxo Lab Ltd | Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3943124A (en) * | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
GB1384372A (en) | 1971-01-20 | 1975-02-19 | Glaxo Lab Ltd | Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids |
US3686978A (en) | 1971-04-09 | 1972-08-29 | Fairfied Mfg Co Inc | Plantetary reduction wheel hub |
US4093721A (en) * | 1974-08-30 | 1978-06-06 | Glaxo Laboratories Limited | Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof |
GB2137206B (en) * | 1980-02-15 | 1985-04-03 | Glaxo Group Ltd | Androstane 17-carbothioc acid derivatives |
SE449106B (sv) * | 1980-07-10 | 1987-04-06 | Otsuka Pharma Co Ltd | Steroid med anti-inflammatorisk verkan samt komposition innehallande denna |
US4996335A (en) | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
WO1989003390A1 (en) * | 1987-10-13 | 1989-04-20 | Bodor Nicholas S | Soft steroids having anti-inflammatory activity |
US5990099A (en) | 1988-10-31 | 1999-11-23 | Alcon Laboratories, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
US5552438A (en) * | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
AU692892B2 (en) | 1994-06-15 | 1998-06-18 | Wellcome Foundation Limited, The | Enzyme inhibitors |
US6172054B1 (en) * | 1995-06-15 | 2001-01-09 | Alcon Laboratories, Inc. | Combination therapy for lowering and controlling intraocular pressure |
WO1997041867A1 (en) | 1996-05-09 | 1997-11-13 | Alcon Laboratories, Inc. | Use of steroid compounds to prevent non-cancerous tissue growth |
MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
US6245804B1 (en) * | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
AU9281198A (en) * | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzofuran derivatives |
AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
DE69918422T2 (de) | 1998-03-14 | 2005-08-11 | Altana Pharma Ag | Phthalazinone als PDE3/4 Inhibitoren |
GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
CN1353717A (zh) | 1999-05-04 | 2002-06-12 | 莱加制药公司 | 四环黄体酮受体调节剂化合物及其方法 |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US6263209B1 (en) | 1999-07-28 | 2001-07-17 | Motorola, Inc. | Method and apparatus in a wireless communication system for creating a learning function |
CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
GB0015876D0 (en) * | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
AR032361A1 (es) * | 2000-08-05 | 2003-11-05 | Glaxo Group Ltd | Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos |
AR035205A1 (es) | 2000-09-29 | 2004-05-05 | Glaxo Group Ltd | Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas |
AU1770901A (en) | 2000-11-16 | 2002-05-27 | Alcon Lab Inc | Combination therapy for lowering and controlling intraocular pressure |
GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
ES2296923T3 (es) | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
HUP0400070A2 (hu) * | 2001-04-30 | 2004-04-28 | Glaxo Group Limited | 17alfa-helyzetben ciklusos észtercsoportot tartalmazó androsztán-17béta-karbotiosav-észter-származékok mint gyulladásgátló szerek, eljárás a vegyületek előállítására és ezeket tartalmazó gyógyszerkészítmények |
EP2042168B1 (en) | 2001-09-14 | 2013-10-23 | Glaxo Group Limited | Inhalation formulation comprising phenethanolamine derivatives for the treatment of respiratory diseases |
GB0125259D0 (en) * | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
US6960581B2 (en) | 2002-01-14 | 2005-11-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof |
AU2003202044A1 (en) | 2002-01-15 | 2003-09-09 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
WO2003061651A1 (en) | 2002-01-22 | 2003-07-31 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
ES2298508T3 (es) | 2002-03-26 | 2008-05-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos. |
AU2003230700A1 (en) | 2002-03-26 | 2003-10-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US6897224B2 (en) * | 2002-04-02 | 2005-05-24 | Schering Ag | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
ATE496620T1 (de) | 2002-04-11 | 2011-02-15 | Merck Sharp & Dohme | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren |
DE60318193T2 (de) | 2002-04-25 | 2008-12-04 | Glaxo Group Ltd., Greenford | Phenethanolaminderivate |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
JP4503436B2 (ja) | 2002-07-08 | 2010-07-14 | ファイザー・プロダクツ・インク | 糖質コルチコイド受容体のモジュレーター |
EP1575502B1 (en) | 2002-07-18 | 2010-01-20 | Bristol-Myers Squibb Company | Compositions and methods involving nuclear hormone receptor site ii |
PL375442A1 (en) | 2002-07-18 | 2005-11-28 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
AU2003259747A1 (en) | 2002-08-21 | 2004-03-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
BR0314392A (pt) | 2002-09-16 | 2005-07-12 | Glaxo Group Ltd | Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
WO2004026248A2 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
WO2004037807A2 (en) | 2002-10-22 | 2004-05-06 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
RU2332400C2 (ru) | 2002-10-28 | 2008-08-27 | Глаксо Груп Лимитед | Производные фенэтаноламина для лечения респираторных заболеваний |
GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
-
2003
- 2003-07-11 GB GBGB0316290.6A patent/GB0316290D0/en not_active Ceased
-
2004
- 2004-07-08 AR ARP040102427A patent/AR045900A1/es unknown
- 2004-07-08 AR ARP040102428A patent/AR045901A1/es unknown
- 2004-07-09 DK DK04763226.0T patent/DK1644398T3/da active
- 2004-07-09 CN CN2011102290522A patent/CN102372756A/zh active Pending
- 2004-07-09 KR KR1020067000690A patent/KR101029207B1/ko active IP Right Grant
- 2004-07-09 RU RU2005141226/04A patent/RU2359973C2/ru active
- 2004-07-09 EP EP04741020A patent/EP1644397B1/en active Active
- 2004-07-09 DE DE602004027137T patent/DE602004027137D1/de active Active
- 2004-07-09 ES ES04741020T patent/ES2343685T3/es active Active
- 2004-07-09 WO PCT/EP2004/007820 patent/WO2005005452A1/en active Application Filing
- 2004-07-09 MY MYPI20042746A patent/MY140987A/en unknown
- 2004-07-09 PL PL04741020T patent/PL1644397T3/pl unknown
- 2004-07-09 SI SI200431471T patent/SI1644397T1/sl unknown
- 2004-07-09 AU AU2004255854A patent/AU2004255854B2/en not_active Ceased
- 2004-07-09 JP JP2006518180A patent/JP4709751B2/ja not_active Expired - Fee Related
- 2004-07-09 NZ NZ544577A patent/NZ544577A/en unknown
- 2004-07-09 MX MXPA06000442A patent/MXPA06000442A/es active IP Right Grant
- 2004-07-09 KR KR1020067000738A patent/KR101075324B1/ko active IP Right Grant
- 2004-07-09 CA CA2531911A patent/CA2531911C/en not_active Expired - Fee Related
- 2004-07-09 EP EP11151276.0A patent/EP2380898B1/en active Active
- 2004-07-09 CN CN2004800255908A patent/CN1845933B/zh not_active Expired - Fee Related
- 2004-07-09 DK DK04741020.4T patent/DK1644397T3/da active
- 2004-07-09 ES ES04763226T patent/ES2400821T3/es active Active
- 2004-07-09 AT AT04741020T patent/ATE467638T1/de active
- 2004-07-09 EP EP04763226A patent/EP1644398B1/en active Active
- 2004-07-09 US US10/564,299 patent/US7291609B2/en active Active
- 2004-07-09 ES ES11151276T patent/ES2433665T3/es active Active
- 2004-07-09 MY MYPI20042752A patent/MY137944A/en unknown
- 2004-07-09 TW TW093120698A patent/TWI367888B/zh not_active IP Right Cessation
- 2004-07-09 PL PL04763226T patent/PL1644398T3/pl unknown
- 2004-07-09 US US10/564,325 patent/US7288536B2/en active Active
- 2004-07-09 SI SI200432006T patent/SI1644398T1/sl unknown
- 2004-07-09 AU AU2004255855A patent/AU2004255855B2/en not_active Ceased
- 2004-07-09 PT PT47632260T patent/PT1644398E/pt unknown
- 2004-07-09 CA CA2531905A patent/CA2531905C/en not_active Expired - Fee Related
- 2004-07-09 WO PCT/EP2004/007819 patent/WO2005005451A1/en active Application Filing
- 2004-07-09 NZ NZ544576A patent/NZ544576A/en unknown
- 2004-07-09 PT PT04741020T patent/PT1644397E/pt unknown
- 2004-07-09 CN CN2004800256690A patent/CN1849330B/zh not_active Expired - Fee Related
- 2004-07-09 MX MXPA06000443A patent/MXPA06000443A/es active IP Right Grant
- 2004-07-09 BR BRPI0412526-6A patent/BRPI0412526A/pt not_active Application Discontinuation
- 2004-07-09 JP JP2006518181A patent/JP4709752B2/ja not_active Expired - Fee Related
- 2004-07-09 TW TW093120707A patent/TWI338694B/zh not_active IP Right Cessation
- 2004-07-09 RU RU2005141064/04A patent/RU2348645C2/ru active
- 2004-07-09 BR BRPI0412527-4A patent/BRPI0412527A/pt not_active Application Discontinuation
-
2005
- 2005-12-22 IL IL172776A patent/IL172776A/en active IP Right Grant
- 2005-12-22 IL IL172777A patent/IL172777A/en active IP Right Grant
- 2005-12-22 IS IS8193A patent/IS2909B/is unknown
- 2005-12-22 IS IS8194A patent/IS2776B/is unknown
-
2006
- 2006-01-06 MA MA28701A patent/MA27897A1/fr unknown
- 2006-01-06 NO NO20060111A patent/NO333263B1/no not_active IP Right Cessation
- 2006-01-06 MA MA28703A patent/MA27899A1/fr unknown
- 2006-01-06 NO NO20060110A patent/NO332041B1/no not_active IP Right Cessation
- 2006-01-10 ZA ZA200600223A patent/ZA200600223B/en unknown
- 2006-01-10 ZA ZA200600226A patent/ZA200600226B/en unknown
- 2006-08-29 HK HK06109621.2A patent/HK1089185A1/xx not_active IP Right Cessation
- 2006-08-29 HK HK06109622.1A patent/HK1089186A1/xx not_active IP Right Cessation
-
2007
- 2007-09-28 US US11/863,439 patent/US7524970B2/en active Active
- 2007-09-28 US US11/863,390 patent/US7638508B2/en active Active
- 2007-09-28 US US11/863,419 patent/US20080021231A1/en not_active Abandoned
-
2009
- 2009-04-03 RU RU2009112207/04A patent/RU2009112207A/ru not_active Application Discontinuation
-
2010
- 2010-03-01 US US12/714,961 patent/US20100152148A1/en not_active Abandoned
- 2010-06-29 HR HR20100359T patent/HRP20100359T1/hr unknown
- 2010-06-30 CY CY20101100601T patent/CY1110149T1/el unknown
- 2010-12-23 IL IL210209A patent/IL210209A0/en unknown
-
2011
- 2011-01-07 JP JP2011001699A patent/JP2011093929A/ja active Pending
-
2013
- 2013-01-23 HR HRP20130056TT patent/HRP20130056T1/hr unknown
- 2013-03-19 CY CY20131100230T patent/CY1113836T1/el unknown
-
2014
- 2014-10-28 IS IS050094A patent/IS2928B/is unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3856828A (en) | 1972-07-19 | 1974-12-24 | Glaxo Lab Ltd | Anti-inflammatory steroids of the androstane series having a halo-substituted c{11 {14 c{11 {11 alkoxy carbonyl group at the 17{62 {0 position |
GB1514476A (en) | 1974-08-30 | 1978-06-14 | Glaxo Lab Ltd | Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101075324B1 (ko) | 항염증 활성을 가지는 특이적 글루코코르티코스테로이드화합물 | |
EP1836215B1 (en) | Androstane 17-alpha-carbonate for use in the treatment of inflammatory and allergic conditions | |
JP5281291B2 (ja) | 新規化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140929 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150930 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160929 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170919 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180918 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190917 Year of fee payment: 9 |